News

• Request for peer-reviewed publications in ATMP

• Online Resource: New Horizons in the Management of ADA-SCID

• VIVEbiotech makes a capital increase of 3.5 million euros to complete its expansion plan

• This week in gene and cell therapy - 26 July 2019

• This week in gene and cell therapy - 19 July 2019

• This week in gene and cell therapy - 12 July 2019

• This week in gene and cell therapy - 5 July 2019

• This week in gene and cell therapy - 28 June 2019

• VIVEbiotech receives an issue notification of the patent grant for the LENTISOMA technology from the United States Patent and Trademark Office

• This week in gene and cell therapy - 21 June 2019

• This week in gene and cell therapy - 7 June 2019

• This week in gene and cell therapy - 31 May 2019

• This week in gene and cell therapy - 24 May 2019

• This week in gene and cell therapy - 17 May 2019

• This week in gene and cell therapy - 10 May 2019

• This week in gene and cell therapy - 3 May 2019

• This week in gene and cell therapy - 26 April 2019

• This week in gene and cell therapy - 12 April 2019

• This week in gene and cell therapy - 5 April 2019

• John Bell and Lisa Riedmayr win inaugural ESGCT PPE Award

• This week in gene and cell therapy - 8 March 2019

• This week in gene and cell therapy - 22 February 2019

• This week in gene and cell therapy - 15 February 2019

• This week in gene and cell therapy - 1 February 2019

• Call for applications: EKFS Award for Medical Research (€ 2.5 million)

• This week in gene and cell therapy - 25 January 2019

• This week in gene and cell therapy - 18 January 2019

• This week in gene and cell therapy - 4 January 2019

• This week in gene and cell therapy - 14 December 2018

• This week in gene and cell therapy - 7 December 2018

• Consensus statement of European Societies of Gene and Cell Therapy on the reported birth of genome-edited babies in China

• This week in gene and cell therapy - 23 November 2018

• This week in gene and cell therapy - 16 November 2018

• This week in gene and cell therapy - 9 November 2018

• This week in gene and cell therapy - 2 November 2018

• Call for proposals: gene-based therapeutic approaches for treatment of neurofibromatosis(2x $240.000 available)

• This week in gene and cell therapy - 7 September 2018

• This week in gene and cell therapy - 31 August 2018

• This week in gene and cell therapy - 24 August 2018

• This week in gene and cell therapy - 10 August 2018

• This week in gene and cell therapy - 3 August 2018

• This week in gene and cell therapy - 20 July 2018

• This week in gene and cell therapy - 13 July 2018

• This week in gene and cell therapy - 6 July 2018

• This week in gene and cell therapy - 22 June 2018

• This week in gene and cell therapy - 15 June 2018

• This week in gene and cell therapy - 8 June 2018

• This week in gene and cell therapy - 1 June 2018

• AFM- Téléthon call for projects on Bioproduction Breakthrough in Gene Therapy Technologies

• This week in gene and cell therapy - 25 May 2018

• This week in gene and cell therapy - 18 May 2018

• This week in gene and cell therapy - 4 May 2018

• This week in gene and cell therapy - 27 April 2018

• This week in gene and cell therapy - 20 April 2018

• This week in gene and cell therapy - 6 April 2018

• Promising results of stem cell therapy for MS

• This week in gene and cell therapy - 9 March 2018

• This week in gene and cell therapy - 16 February 2018

• This week in gene and cell therapy - 2 February 2018

• This week in gene and cell therapy - 19 January 2018

• This week in gene and cell therapy - 12 January 2018

• This week in gene and cell therapy - 5 January 2018

• 2017 breakthroughs in medicine dominated by gene and cell therapy

• FDA approved Luxturna, a gene therapy product for inherited blindness

• This week in gene and cell therapy - 8 December 2017

• 2017 ESGCT DG-GT Congress Education Day video now online

• This week in gene and cell therapy - 1 December 2017

• This week in gene and cell therapy - 24 November 2017

• This week in gene and cell therapy - 3 November 2017

• This week in gene and cell therapy - 27 October 2017

• New base editor extends machinery to correct single base pair mutations

• This week in gene and cell therapy - 6 October 2017

• First FDA approval for CAR-T cell therapy

• First report of JCAR017 trial: CAR-T cell activity observed in the brain

• Gene addition of micro-dystrophin improves Duchenne muscular dystrophy symptoms in dogs

• Proof of concept for new strategy of genome editing to correct splice-site mutations

• Step forward for precision medicine - personalised anti-cancer vaccine tested in patients

• Mesenchymal stem cells reverse tissue damage in mouse model of asthma

• Genome editing used to treat Huntington's disease in mice

• Using genome editing to treat chronic inflammation

• New genome editing resources for patients and families

• First report from diabetes islet transplantation trial NCT02213003

• ESGCT launches Gene & Cell Therapy Community Heatmap

• New developments in blood cell therapy

• First clinical trial with in vivo genome editing

• Phase I trial of gene therapy for age-related macular degeneration completed

• ESGCT welcomes two Student Board Members

• Feng Zhang Discusses CRISPR and Future of Gene Editing in Interview in Human Gene Therapy

• New gene therapy success in a rare disease of the immune system: Wiskott-Aldrich syndrome

• First stem-cell therapy recommended for approval in EU